Noëlle Dommann

Mrs. Noëlle Dommann


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 October 2019 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
JGJacopo Gavini
Jacopo Gavini
NDNoëlle Dommann
Noëlle Dommann
MJManuel O. Jakob
Manuel O. Jakob
AKAdrian Keogh
Adrian Keogh
LBLaure C. Bouchez
Laure C. Bouchez
VBVanessa Banz
Vanessa Banz
Lysosomal sequestration of anti-cancer compounds reduces drug availability at intracellular target sites, thereby limiting drug-sensitivity and inducing chemoresistance. For hepatocellular carcinoma (HCC), sorafenib (SF) is the first line systemic treatment, as well as a simultaneous activator of autophagy-induced drug resistance. The purpose of this study is to elucidate how combination therapy with the FDA-approved photosensitizer verteporfin (VP) can potentiate the antitumor effect of SF, overcoming its acquired resistance mechanisms. HCC cell lines and patient-derived in vitro and in vivo preclinical models were used to identify the molecular mechanism of action of VP alone and in combination with SF. We demonstrate that SF is lysosomotropic and increases the total number of lysosomes in HCC cells and patient-derived xenograft model. Contrary to the effect on lysosomal stability by SF, VP is not only sequestered in lysosomes, but induces lysosomal pH alkalinization, lysosomal membrane permeabilization (LMP) and tumor-selective proteotoxicity. In combination, VP-induced LMP potentiates the antitumor effect of SF, further decreasing tumor proliferation and progression in HCC cell lines and patient-derived samples in vitro and in vivo. Our data suggest that combination of lysosome-targeting compounds, such as VP, in combination with already approved chemotherapeutic agents could open a new avenue to overcome chemo-insensitivity caused by passive lysosomal sequestration of anti-cancer drugs in the context of HCC.

15 July 2020 in Cancers
Verified
Journal Article
Open access
PDF file
NDNoëlle Dommann
Noëlle Dommann
DSDaniel Sanchez-Taltavull
Daniel Sanchez-Taltavull
LELinda Eggs
Linda Eggs
FBFabienne Birrer
Fabienne Birrer
TBTess Brodie
Tess Brodie
DSDeborah Stroka
Deborah Stroka
Colorectal cancer, along with its high potential for recurrence and metastasis, is a major health burden. Uncovering proteins and pathways required for tumor cell growth is necessary for the development of novel targeted therapies. Ajuba is a member of the LIM domain family of proteins whose expression is positively associated with numerous cancers. Our data shows that Ajuba is highly expressed in human colon cancer tissue and cell lines. Publicly available data from The Cancer Genome Atlas shows a negative correlation between survival and Ajuba expression in patients with colon cancer. To investigate its function, we transduced SW480 human colon cancer cells, with lentiviral constructs to knockdown or overexpress Ajuba protein. The transcriptome of the modified cell lines was analyzed by RNA sequencing. Among the pathways enriched in the differentially expressed genes, were cell proliferation, migration and differentiation. We confirmed our sequencing data with biological assays; cells depleted of Ajuba were less proliferative, more sensitive to irradiation, migrated less and were less efficient in colony formation. In addition, loss of Ajuba expression decreased the tumor burden in a murine model of colorectal metastasis to the liver. Taken together, our data supports that Ajuba promotes colon cancer growth, migration and metastasis and therefore is a potential candidate for targeted therapy.

15 June 2022 in FEBS Letters
Verified
Journal Article
Open access
NDNoëlle Dommann
Noëlle Dommann
JGJacopo Gavini
Jacopo Gavini
DSDaniel Sanchez-Taltavull
Daniel Sanchez-Taltavull
FBFelix Alexander Baier
Felix Alexander Baier
FBFabienne Birrer
Fabienne Birrer
DSDeborah Stroka
Deborah Stroka
The LIM‐domain protein Ajuba is associated with cell proliferation, a fundamental process of tissue regeneration and cancer. We report that in the liver, Ajuba expression is increased during regeneration and in tumour cells and tissues. Knockout of Ajuba using CRISPR/Cas9 is embryonic lethal in mice. shRNA targeting of Ajuba reduces cell proliferation, delays cell entry into S‐phase, reduces cell survival and tumour growth in vivo and increases expression of the DNA damage marker γH2AX. Ajuba binding partners include proteins involved in DNA replication and damage, such as SKP2, MCM2, MCM7 and RPA70. Taken together, our data support that Ajuba promotes liver cell proliferation associated with development, regeneration and tumour growth and is involved in DNA replication and damage repair.

1 August 2026 in Development
Verified
Journal Article
Open access
MYMehmet Yildiz
Mehmet Yildiz
NDNoëlle Dommann
Noëlle Dommann
THTugce Kardelen Hasdemir
Tugce Kardelen Hasdemir
EVEsther de Vries
Esther de Vries
AAAnna Alemany
Anna Alemany
NGNiels Geijsen
Niels Geijsen
Axial elongation and cell fate decisions during early embryonic development are regulated by gradients of signaling molecules, such as retinoic acid (RA) and fibroblast growth factor (FGF). To assess the role of RA in vitro, studies have relied on its direct addition to the medium, which can produce teratogenic effects. Here, we examined the role of a RA precursor, retinol, on axial elongation, anteroposterior development, and FGF-dependent signaling in murine gastruloids, an in vitro model system for early embryogenesis. Rather than applying RA ectopically, we supplemented a retinoid-free medium with its precursor, retinol, prompting the cells to produce RA endogenously. Our results showed that the spatiotemporal RA and FGF signaling can be manipulated with different doses of retinol, influencing gastruloid elongation and lineage specification. Gastruloids cultured in high doses of retinol showed an enrichment of ectoderm, whereas low doses resulted in early mesoderm specification and increased FGF signaling. We further used our approach to confirm that RA signaling inhibits FGF in gastruloids. Thus, retinol can modulate cellular composition in gastruloids, allowing us to investigate fate commitment of ectoderm and mesoderm progenitors in vitro.